- Home
- PVLA vs MYGN Comparison
PVLA vs MYGN Comparison
Compare PVLA & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- MYGN
- Stock Information
- Founded
- PVLA 2015
- MYGN 1991
- Country
- PVLA United States
- MYGN United States
- Employees
- PVLA N/A
- MYGN N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PVLA Health Care
- MYGN Health Care
- Exchange
- PVLA Nasdaq
- MYGN Nasdaq
- Market Cap
- PVLA 604.2M
- MYGN 642.0M
- IPO Year
- PVLA N/A
- MYGN 1995
- Fundamental
- Price
- PVLA $65.78
- MYGN $8.06
- Analyst Decision
- PVLA Strong Buy
- MYGN Hold
- Analyst Count
- PVLA 12
- MYGN 13
- Target Price
- PVLA $66.67
- MYGN $13.50
- AVG Volume (30 Days)
- PVLA 179.9K
- MYGN 1.6M
- Earning Date
- PVLA 11-15-2025
- MYGN 11-06-2025
- Dividend Yield
- PVLA N/A
- MYGN N/A
- EPS Growth
- PVLA N/A
- MYGN N/A
- EPS
- PVLA N/A
- MYGN N/A
- Revenue
- PVLA N/A
- MYGN $832,900,000.00
- Revenue This Year
- PVLA N/A
- MYGN $0.17
- Revenue Next Year
- PVLA N/A
- MYGN $6.19
- P/E Ratio
- PVLA N/A
- MYGN N/A
- Revenue Growth
- PVLA N/A
- MYGN 3.83
- 52 Week Low
- PVLA $11.17
- MYGN $3.76
- 52 Week High
- PVLA $65.80
- MYGN $27.26
- Technical
- Relative Strength Index (RSI)
- PVLA 70.90
- MYGN 65.50
- Support Level
- PVLA $60.49
- MYGN $7.04
- Resistance Level
- PVLA $65.57
- MYGN $7.97
- Average True Range (ATR)
- PVLA 3.63
- MYGN 0.39
- MACD
- PVLA 0.19
- MYGN -0.05
- Stochastic Oscillator
- PVLA 99.83
- MYGN 95.33
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.